EGFR and glioblastoma: One of the key drivers of glioblastoma progression is the dysregulation of several critical signaling pathways, including those involving the EGFR and the phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) axis [8,9].